Aclaris Therapeutics and a subsidiary of Sun Pharma collaborate on a licensing deal

6 Dec 2023 , 12:03 PM

Aclaris Therapeutics, Inc., a biopharmaceutical company that specialises in cutting-edge medications for immuno-inflammatory illnesses, and Sun Pharmaceutical Industries, Inc. announced a licencing deal on December 6.

Under the terms of the agreement, Aclaris granted Sun Pharma exclusive rights to certain patents pertaining to the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic versions of ruxolitinib for the treatment of androgenetic alopecia (AGA) or alopecia areata (AA).

According to the company’s exchange statement, the agreement comprises royalties, regulatory and commercial milestones, and an initial payment of $15 million.

For feedback and suggestions, write to us at [e-mail]